Skip to content

Evaluation of nocturnal digital cough monitoring in people with chronic lung disease

Evaluation of nocturnal digital cough monitoring in people with chronic lung disease - CoughMon

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035481
Enrollment
250
Registered
2024-11-08
Start date
2025-01-09
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E84

Interventions

Group 1: Patients with cystic fibrosis and healthy participants receive digital nocturnal cough monitoring using a smartphone app. This will be used to investigate the natural course of cough under st

Sponsors

Charité - Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of Cystic Fibrosis Availability of a smartphone

Exclusion criteria

Exclusion criteria: Comorbid condition likely to affect the patients cough frequency (e.g. post lung transplantation) or ability to adhere to monitoring. The regular presence of a person of the same sex during nocturnal cough monitoring is also an exclusion criterion, as this may influence cough monitoring.

Design outcomes

Primary

MeasureTime frame
Nocturnal cough in CF patients receiving standard of care CF treatment and healthy controls

Secondary

MeasureTime frame
relationship between nocturnal cough frequency and CF lung disease severity measured by FEV1pp relationship between nocturnal cough frequency and pulmonary exacerbation according identification of individual thresholds at which normal variability is exceeded and incipient lung deterioration can be assumed allowing for an alert system

Countries

France, Germany, Ireland

Contacts

Public ContactMarcus Mall

Charité- Universitätsmedizin Berlin

marcus.mall@charite.de+4930450566182

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026